As America’s biopharmaceutical companies work around the clock to combat COVID-19, a disease caused by a novel strain of coronavirus, now is an important time to consider how we can prepare for the next public health emergency: Antimicrobial resistance (AMR).

America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19. We are working around the clock to research and develop new vaccines and treatments, as well as testing existing medicines to help those infected with the virus. In addition, our companies are committed to supporting health care workers who are on the frontlines and communities around the world affected by COVID-19.

Takeda is closely monitoring the novel coronavirus (COVID-19) outbreak and the global response. As a company dedicated to the health and well-being of people around the globe, we are committed to taking steps to help those impacted by the coronavirus.

The global COVID-19 outbreak has upended our regular routines, shut down our schools and workplaces, and made terms like “social distancing” and “flatten the curve” part of our everyday conversations.

As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States, both the private and public sectors are working around the clock to find solutions

External Content Promo Description

America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, a novel strain of coronavirus that originated in Wuhan, China. In addition to applying their scientific expertise to find ways to diagnose, treat and prevent infections from the virus, the biopharmaceutical industry is providing financial support and in-kind donations to organizations and collaborating with U.S., Chinese, and global health authorities to combat this global public health emergency.

External Content Promo Description